BRAHMS, Cezanne, and Lumiphore have signed an agreement to incorporate Lumiphore’s Lumi4 -Tb complexes in BRAHMS diagnostic tests.
Lumi4-Tb would increase sensitivity of BRAHMS diagnostic tests and allow the development of multiplexed assays (measuring 3-4 parameters in one test sample).
Under the agreement, BRAHMS and Cezanne have the non-exclusive rights to incorporate Lumi4 technology into current and future diagnostic tests, and the exclusive rights to use the technology in diagnostic tests for Down’s Syndrome (including Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism).
Ansgar Schmitt, Vice President of Business Development, BRAHMS, said: “Using Lumi4-Tb in the reader technology of our diagnostic tests will provide multiple benefit for BRAHMS. Thus we will take Lumi4-Tb into consideration for the development of future analysis systems, both in laboratories and point-of-care-formats.”